Goldman Sachs lowered the firm’s price target on Mirion (MIR) to $29 from $33 and keeps a Buy rating on the shares. Mirion posted Q4 adjusted EBITDA of $77.6M, driven by strong Medical segment margins, with orders exceeding $400M for the first time, the analyst tells investors in a research note. Despite the stock selling off on weaker organic growth and a backloaded 2H26 guide, the Nuclear segment outlook remains strong, presenting a potential buying opportunity, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIR:
- Mirion price target lowered to $29 from $32 at Citi
- Mirion announces executive appointments to accelerate strategic growth
- Mirion: Strong Profitability, Backlog Growth, and 2026 Outlook Support Buy Rating and Upside Potential
- Mirion reports Q4 adjusted EPS 15c, consensus 16c
- Mirion sees FY26 adjusted EPS 50c-57c, consensus 61c